Efficacy of Purslane in Treatment of Oral Lichen Planus
关键词
抽象
描述
Oral lichen planus is a chronic common inflammatory disorder affecting stratified squamous epithelia. The majority problem of OLP is development of oral squamous cell carcinoma , irrespective of the clinical type of OLP and therapy. Previous study demonstrated a decreased antioxidant defence and increased oxidative damage to lipids, DNA and proteins in lichen planus .This oxidative modifications point to pathophysiological alterations mainly within the basal cell layers of epidermis and at the dermoepidermal junction. So oxidative stress could be effective in pathogenesis of OLP. Purslane is an excellent source of vitamin A,C and E and essential amino acids, has been described as a power food of the future because of its high nutritive and antioxidant properties. Purslane also decreased the level of TNF-α and IL6, that are responsible for up-regulated adhesion molecules (in OLP lymphocyte T (T cell) recruited and retained in sub mucosa through receptors to endothelial adhesion molecule. and basal keratinocytes undergo apoptosis). The purpose of the study was to determined the efficacy of Purslane in the treatment of oral lichen planus.
日期
| 最后验证: | 08/31/2010 |
| 首次提交: | 09/01/2008 |
| 提交的预估入学人数: | 09/02/2008 |
| 首次发布: | 09/03/2008 |
| 上次提交的更新: | 09/06/2010 |
| 最近更新发布: | 09/07/2010 |
| 实际学习开始日期: | 03/31/2006 |
| 预计主要完成日期: | 04/30/2008 |
| 预计完成日期: | 07/31/2008 |
状况或疾病
干预/治疗
Drug: 1
Drug: 2
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Active Comparator: 1 Patients with oral lichen planus | Drug: 1 Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months |
| Placebo Comparator: 2 Patients with oral lichen planus | Drug: 2 Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months . |
资格标准
| 有资格学习的年龄 | 25 Years 至 25 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Biopsy confirmed symptomatic oral lichen planus: WHO histological criteria in combination with clinical appearance will be used for diagnosis - Patients who had symptoms such as burning sensation, pain - Patients not on any immunosuppressive or immunomodulatory treatment. In case they were,then such treatment should be stopped and a washout period of 1 month was given. - Patients of both sexes between 30 to 70 year's old - Patients who gave written informed consent - Patients who were willing for evaluation in second week after therapy and every 1 month up to 6 months Exclusion Criteria: - The presence of histological signs of dysplasia - Patients suffering from any localized or systemic disease - Renal disease patients - Pregnant patients - Patients who can not continue the study for private or social reasons - Patients who used lichenoid reaction including drugs |
结果
主要结果指标
1. Relief sign &symptom and clinical features [(every 1 month up to 6months)]
次要成果指标
1. Relief sign &symptom and clinical features [(time frame6 months)]
